StocksShanghai Fosun Pharmaceutical02196.HK

02196.HK

Shanghai Fosun Pharmaceutical

18.55 0.14 (0.76%)
Prices By Xignite, in HKD Market Closed
Trade
S
18.55
B
18.63

Overview

Prev Close18.55
Day's Range 18.13 - 19.21
52 Week Range 18.13 - 44.01
Average Volume (3m)5.95M
1-Year Return-53.92%
Beta0.1103
Market Cap56.6B
P/E Ratio9.52
Revenue52.29B
EPS1.7959
Dividend (Yield)0.66 (3.56%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Pharmaceuticals Major
CEO Yu Qing Chen; De Yong Wen, MBA
Employees 36,279

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Shanghai Fosun Pharmaceutical's revenues increased by 38.17% and amounted to 46.83B. Net income increased by 35.77% to 6.01B. Net assets increased by 8.55% to 59.11B and EPS increased from 1.61 to 2.23.
02196.HK's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
45.22%
Net Profit Margin
12.80%
Operating Margin
5.96%
Return On Investment
8.01%
12/18
03/19
06/19
09/19
Total Revenue
7.59B
7.76B
8.48B
7.81B
Gross Profit
4.24B
4.56B
5.02B
4.53B
Operating Income
359.59M
832.08M
860.37M
578.62M
Net Income
770.6M
989.63M
1.11B
709.71M